Enasidenib - Celgene

Drug Profile

Enasidenib - Celgene

Alternative Names: AG 221 mesylate; AG-221; AGI 12910 mesylate; AGI-12910; CC-90007; IDHIFA

Latest Information Update: 18 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Celgene Corporation
  • Class Antineoplastics; Propanols; Pyridines; Small molecules; Triazines
  • Mechanism of Action Isocitrate dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase I/II Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 25 Dec 2017 M.D. Anderson Cancer Center in collaboration with Celgene plans a phase II trial for Myelodysplastic Syndrome in USA (NCT03383575)
  • 11 Dec 2017 Safety and efficacy data from a phase I trial in Acute myeloid leukaemia presented at the 59th Annual Meeting of the American Society of Haematology (ASH-2017)
  • 11 Dec 2017 Safety and efficacy data from a phase Ib/II trial in Acute myeloid leukaemia presented at the 59th Annual Meeting of the American Society of Haematology (ASH-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top